This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Medical Care AG & Co. KGaA (“the company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, today introduced the 2008K@home, a hemodialysis system for use at the patient’s home, at the American Society of Nephrology’s Kidney Week 2011 meeting in Philadelphia, USA. The 2008K@home machine is built on the 2008 ® series hemodialysis machine platform that has delivered superior hemodialysis therapy for over 30 years. This machine combines safety, efficacy and reliability with a simple user-interface that incorporates an on-screen tutorial to walk the user through set-up, treatment, and disconnection from therapy. Earlier this year, the U.S. Food and Drug Administration (FDA) cleared the 2008K@home machine for use. “With the growing interest in home therapies in the U.S., the 2008K@home machine provides another option for delivering hemodialysis to patients who want the freedom associated with being at home,” said Maureen Lyden-Green, Vice President for Home Therapies at Fresenius Medical Care North America. “The 2008K@home provides patients with a smaller version of the in-center machine and allows flexibility to deliver a customized physician’s dialysis prescription for each patient, meeting the patient’s medical needs and suiting their lifestyle,” continued Chief Medical and Regulatory Affairs Officer Dr. Jose Diaz-Buxo. Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. Through its network of 2,874 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 228,239 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. For more information about Fresenius Medical Care, visit the Company’s website at www.fmc-ag.com. Disclaimer